






































Postpartum HIV care continuum outcomes
in the southeastern USA
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Objective: The aim of this study was to evaluate postpartum HIV care outcomes.
Design: A prospective clinical cohort of women with HIV and a live birth at the
University of North Carolina, 1996–2014.
Methods: We estimated two stages of the HIV care continuum in the first 24 months
postpartum: care retention (at least two visits per year,90 days apart) and viral suppression
(HIV RNA<400 copies/ml). Multivariable models were fit using logistic regression.
Results: Among 1416 women, 141 experienced a live birth at a median age of 28 years,
with 74% virally suppressed at delivery. Among all women, 48% were retained in care
and 25% maintained viral suppression for the first 24 months postpartum. Among
women with available HIV RNA measures, 42% were suppressed at 24 months. HIV
care retention estimates were stable across calendar years, but viral suppression rates at
24 months postpartum, among women with available HIV RNA measures, increased
from 33 to 67% from 1996–2001 to 2009–2014 (P¼0.04). Being at least 30 years old
was positively, and receiving less than 12 weeks of antenatal antiretroviral therapy was
negatively, associated with HIV care retention at 24 months postpartum [adjusted odds
ratio (AOR): 2.41, 95% confidence interval (95% CI): 1.09–5.29 and AOR: 0.27, 95%
CI: 0.08–0.86]. Older maternal age and viral suppression at delivery were both
positively associated with virologic suppression at 24 months postpartum (AOR:
2.52, CI: 1.02–6.22, and AOR: 6.42 CI: 1.29–31.97, respectively).
Conclusion: HIV care continuum outcomes decrease substantially postpartum, with
younger women and those with less antenatal HIV care less likely to successfully remain
engaged in HIV care following childbirth.
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Introduction
Antiretroviral therapy (ART) is highly effective in
preventing mother to child transmission (MTCT) of
HIV [1–4]. With routine HIV testing, ART provision
and other MTCT prevention interventions, the number
of perinatally infected infants born annually in the USA
has decreased dramatically. An MTCTelimination goal of
less than one perinatal HIV infection per 100 000 live
births has been set by the U.S. Centers for Disease
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Control and Prevention, and though this goal has not yet
been achieved, recent rates have fallen from 1.8 to 1.1
perinatal infections per 100 000 live births between 2010
and 2014 [5,6].
Recommendations for ART during pregnancy, and
among women of childbearing age, have undergone
marked changes over time [1,3,4]. Pregnancy is a critical
time for HIV care, and protecting the health of the foetus
is a clear incentive for women to engage in care [7]. The
postpartum period is also an important time for maternal
engagement in HIV care, but following childbirth,
women may face substantial challenges attending clinical
appointments and adhering to ART. Although limited,
the studies conducted in the United States to date suggest
that women may not receive optimal HIV care
postpartum [8–12]. Furthermore, postpartum ART
adherence may also be lower than ART adherence
during pregnancy leading to lower virologic suppression
rates following childbirth [13–17].
The HIV care continuum model describes the stages from
HIV testing and diagnosis through HIV RNA suppres-
sion, with recent United States estimates suggesting that
as few as 30% of people living with HIV (PLWH), and
26% of women living with HIV (WLWH), have
undetectable HIV RNA levels [18–20]. To date, little
information is available on the HIV care experiences of
pregnant WLWH in the United States, including
postpartum HIV care engagement. In this study, we
evaluated the HIV care continuum for 24 months
postpartum and assessed the effect of demographic and
clinical characteristics on postpartum HIV care engage-
ment and HIV RNA suppression, within a large HIV
clinical cohort in North Carolina.
Materials and methods
Study design and study population
We identified all pregnancies resulting in a live birth
among participants in the University of North Carolina
CFAR HIV Clinical Cohort (UCHCC). The UCHCC
has been previously described, and includes over 5200
patients with HIV, who have received HIV primary care
at a large tertiary care centre in North Carolina since 1996
[21]. UCHCC data collection includes data from
institutionally available electronic health records and
standardized semi-annual medical record reviews, includ-
ing all laboratory data, clinical diagnoses, ART provision
and clinical appointment data. For this study, all
pregnancies recorded after HIV diagnosis underwent
further medical record review for collection of preg-
nancy-specific information.
For these analyses, we included all pregnancies with a live
birth from 1 January 1996 through 31 December 2014, to
allow for at least 2 years of postpartum follow-up, and
only included pregnancies that occurred after women
initiated HIV care at our institution. We excluded two
women who died within 2 years of delivery (one with
disseminated Mycobacterium avium complex, and the other
with dilated cardiomyopathy), and one woman who had a
subsequent pregnancy during the 24-month follow-up.
Pregnancies were included if the women were at least 18
years old and HIV positive at the time of delivery. Among
women with more than one eligible pregnancy during
the time period (18%), we included only the most recent
pregnancy in these analyses, and considered multiple
births as a single observation. UCHCC participants
provided written informed consent, and the UCHCC
and this specific study were approved by the UNC
Institutional Review Board.
Measures
Our primary outcome of interest was engagement in care,
defined using the Institute of Medicine’s (IOM)
definition of attending at least two HIV care visits in a
given year, at least 90 days apart [22,23]. We only
considered attended scheduled visits with an HIV care
provider, and excluded walk-in and emergency care visits.
To account for childbirth hospital stays, we excluded visits
and laboratory tests within 7 days of the delivery date.
Our secondary outcome was HIV RNA suppression,
defined as an HIV RNA level less than 400 copies/ml in a
given year. We excluded HIV RNA measures within 3
months of delivery to provide a washout period, and used
the measure closest to the midpoint of each year. Calendar
years of delivery were categorized into three intervals
(1996–2001, 2002–2008 and 2009–2014), based on
changes in ART use and sample size considerations.
Statistical analysis
We used Kaplan–Meier curves to examine the distribu-
tion of time from delivery to first postpartum HIV care
visit. To test for differences between groups, we used
Fisher’s exact, Chi-square and Mann–Whitney U tests,
and Cochran–Armitage test for trend, as appropriate. To
identify factors associated with our outcomes of interest,
we fit multivariable logistic regression models, including
demographic, clinical and pregnancy-related patient
characteristics. Only factors that were associated with
our outcome of interest with a P value less than 0.20 in
bivariable analyses were included in our final multivari-
able model. For all estimates, 95% confidence intervals
(95% CIs) were calculated, P values were two-sided and
less than 0.05 was considered statistically significant. All
analyses were performed using SAS software version 9.4
(SAS Institute, Cary, North Carolina, USA).
Results
Among 1416 women participating in the UCHCC, 141
had a live birth between 1996 and 2014 and met study
inclusion criteria. The median maternal age at delivery
was 28 years [interquartile range (IQR), 24–32]. Most
women were either non-Hispanic Black (62%) or non-
Hispanic white (21%), with 18% of other race/ethnicity
including 13% Hispanic (Table 1). The median year of
delivery was 2004 (IQR, 2000–2008). Most women had
a prior pregnancy, with gravidity of 1, 2, 3, 4 and at least
5 among 10, 27, 27, 20 and 15%, respectively, and an
overall median gravidity of 3 (IQR, 2–4). The median
number of prior live births was 1 (IQR, 1–2).
Over one-quarter of the women were diagnosed with
HIV during the index pregnancy (28%) (Supplemental
Figure, http://links.lww.com/QAD/B404). The median
number of HIV care visits during pregnancy was 6 among
all women (IQR, 4–8), and did not differ by timing of
HIV diagnosis (P¼ 0.61). Overall, women received a
median of 25 weeks of antenatal ART (IQR, 16–37),
with two women receiving no antenatal ART (1%), and
24 women receiving less than 12 weeks of antenatal ART
(17%). Across calendar time, 11, 21 and 18% received less
than 12 weeks of antenatal ART in years 1996–2001,
2002–2008 and 2009–2014 (P¼ 0.34). Of the women
with less than 12 weeks of ART, 54% were diagnosed
with HIV during the index pregnancy, in comparison to
30% of women receiving 12–38 weeks of ART. At
delivery, the median CD4þ cell count was 491 cells/ml
(IQR, 339–677), with 12 women having a CD4þ cell
count less than 200 cells/ml, and 74% were virologically
suppressed (among women with CD4þ cell count and
HIV RNA levels available at delivery, respectively).
Among women who were not virologically suppressed at
delivery (n¼ 32), the median HIV RNA level was 3.6
log10 copies/ml (IQR, 3.0–4.2). Virologic suppression at
delivery differed across calendar years with 45, 78 and
94% suppressed during 1996–2001, 2002–2008 and
2009–2014 (P< 0.001). Maternal age was also associated
with virologic suppression at delivery, with 67 and 83% of
less than 30 and at least 30-year-old women virologically
suppressed at delivery, respectively (P¼ 0.04).
During follow-up, 36, 58 and 82% had their first HIV
care visit within 30, 60 and 180 days of delivery, with 16
women (11%) attending no HIV care visits in 24 months
of follow-up. The median time to first HIV care visit
among women that had at least one visit was 41 days after
delivery (IQR, 22–75). Among all women, the median
number of HIV care visits in the first 12 months
postpartum was three visits (IQR, 1–6), and two visits
(IQR, 0–4) during 12–24 months postpartum
(P¼ 0.001) (Fig. 1).
Using the IOM criteria as a measure of HIV care
retention, 70 and 48% of women were retained in care at
12 and 24 months postpartum, respectively. Overall, 38%
were virologically suppressed during the first year
postpartum and 25% through two years postpartum.
Among those with available HIV RNA measures, 52 and
42% were suppressed at 12 and 24 months postpartum,
respectively. Postpartum retention in care did not vary
across calendar years (Fig. 2), with little difference across
the three calendar year intervals covering 1996 through
2014 (12-month retention P¼ 0.42; 24-month retention
P¼ 0.24). The proportion of women virologically
suppressed increased across years 1996–2001 to 2009–
2014, with 12-month postpartum virologic suppression
increasing from 26 to 61% (P¼ 0.002), and 24-month
virologic suppression increasing from 19 to 36%
(P¼ 0.09). Among women with available HIV RNA
measures, virologic suppression increased comparing
years 1996–2001 to 2009–2014 from 33 to 80% in
the first 12 months postpartum (P< 0.001), and 33 to
67% in 24 months postpartum (P¼ 0.04).
In multivariable analyses, mothers at least 30 years of age
were more likely to be retained in HIV care based on the
IOM criteria at both 12 and 24 months postpartum
[adjusted odds ratio (AOR): 2.44, 95% CI: 1.00–5.94 and
AOR: 2.41, 95% CI: 1.09–5.29, respectively] (Table 2).
Conversely, receiving less than 12 weeks of ART during
pregnancy, in comparison to 12–38 weeks of ART, was
negatively associated with receiving adequate HIV care at
both 12 and 24 months postpartum (AOR: 0.24, 95% CI:
0.08–0.68, and AOR: 0.27, 95% CI: 0.08–0.86,
respectively).
Older maternal age was also associated with better
virological postpartum outcomes in bivariable and
multivariable analyses (Table 3). Specifically, HIV
RNA suppression at 12 and 24 months postpartum
Table 1. Demographic and clinical characteristics of women living
with HIV at delivery, UCHCC 1996–2014.
Characteristica N¼141
Age <30 years, n (%) 84 (60)
Race, n (%)
White, non-Hispanic 29 (21)
Black, non-Hispanic 87 (62)
Other/Hispanic 25 (18)
Antenatal HIV diagnosis, n (%) 40 (28)
HIV RNA <400 copies/ml, n (%) 90 (74)
CD4þ cell count, median cells/ml (IQR) 491 (339–677)
Antenatal ART use, n (%)
<12 weeks 24 (17)
12–38 weeks 88 (62)
38 weeks 29 (21)











ART, antiretroviral therapy; IQR, interquartile range.
aAll characteristics measured at delivery. Missing data for HIV RNA
























Fig. 1. Postpartum HIV care visit distribution stratified by time from delivery among women living with HIV, UCHCC 1996–2014.


























Fig. 2. Postpartum HIV care continuum among women living with HIV, UCHCC 1996–2014. HIV care retention at 12 and
24 months postpartum defined according to the Institute of Medicine care retention criteria, and virologic suppression as HIV RNA
<400 copies/ml.
was more likely among women at least 30 years of age at
delivery (AOR: 2.74, 95% CI: 1.17–6.41 and AOR:
2.52, 95% CI: 1.02–6.22, respectively). In addition,
virologic suppression at 12 and 24 months postpartum
was also strongly associated with virologic suppression at
delivery, although the estimates were imprecise (AOR:
6.12, 95% CI: 1.53–24.45 and AOR: 6.42, 95% CI:
1.29–31.97, respectively).
Discussion
In this study of WLWH participating in a large
southeastern U.S. clinical cohort with a live birth
between 1996 and 2014, we observed dramatic decreases
in HIV care retention and virologic suppression across 24
months postpartum. Nearly all women received some
ART during pregnancy, and almost three out of four were
Table 2. Characteristics associated with 12 and 24-month postpartum HIV care retention among women living with HIV in the UCHCC, 1996–
2014 (N U 141).
12 Month Retention 24-month retention
Characteristica Unadjusted OR (95% CI) Adjusted OR (95% CI) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age 30 years 2.19 (1.01–4.76) 2.44 (1.00–5.94) 2.46 (1.23–4.90) 2.41 (1.09–5.29)
Race
White, non-Hispanic 1.12 (0.44–2.85) – 1.32 (0.57–3.07) –
Black, non-Hispanic ref – ref –
Other 0.76 (0.30–1.93) – 0.71 (0.29–1.76) –
Antenatal HIV diagnosis 0.88 (0.40–1.93) – 0.54 (0.26–1.15) 0.91 (0.36–2.31)
HIV RNA <400 copies/ml 1.36 (0.57–3.23) – 1.29 (0.57–2.89) –
CD4þ cell count, per 100 cells/ml
increase
1.01 (0.87–1.17) – 1.00 (0.88–1.14) –
Antenatal ART use
<12 weeks 0.18 (0.07–0.46) 0.24 (0.08–0.68) 0.24 (0.08–0.70) 0.27 (0.08–0.86)
12–38 weeks ref ref ref ref
38 weeks 0.77 (0.30–2.01) 0.62 (0.21–1.89) 1.29 (0.55–3.02) 0.96 (0.35–2.60)
Calendar year of delivery
1996–2001 2.40 (1.01–5.71) 2.31 (0.78–6.82) 1.46 (0.68–3.13) –
2002–2008 ref ref ref –
2009–2014 1.73 (0.69–4.35) 1.84 (0.68–4.93) 0.87 (0.37–2.04) –
Gravidity
1 2.86 (0.60–13.58) 3.24 (0.62–16.86) 2.85 (0.83–9.80) 3.65 (0.97–13.73)
2 ref ref ref ref
ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
aAll characteristics measured at delivery. HIV care retention based on the Institute of Medicine criteria.
Table 3. Characteristics associated with 12 and 24-month postpartum HIV viral suppression among women living with HIV in the UCHCC,
1996–2014 (N U 141).
12-month suppression 24-month suppression
Characteristica Unadjusted OR (95% CI) Adjusted OR (95% CI) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age 30 years 3.16 (1.56–6.42) 2.74 (1.17–6.41) 2.92 (1.33–6.41) 2.52 (1.02–6.22)
Race
White, non-Hispanic 1.28 (0.54–3.01) – 2.34 (0.91–5.97) 2.27 (0.75–6.88)
Black, non-Hispanic ref – ref Ref
Other 1.42 (0.58–3.50) – 2.50 (0.94–6.65) 2.55 (0.83–7.82)
Antenatal HIV diagnosis 1.28 (0.61–2.70) – 1.01 (0.43–2.36) –
HIV RNA <400 copies/ml 10.11 (2.87–35.57) 6.12 (1.53–24.45) 7.50 (1.68–33.51) 6.42 (1.29–31.97)
CD4þ cell count, per 100 cells/ml
increase
1.07 (0.93–1.22) – 1.08 (0.93–1.25) –
Antenatal ART use
<12 weeks 0.36 (0.12–1.06) 0.67 (0.18–2.48) 0.53 (0.17–1.72) –
12–38 weeks ref ref ref –
38 weeks 0.97 (0.42–2.28) 0.86 (0.28–2.60) 0.85 (0.32–2.24) –
Calendar year of delivery
1996–2001 0.61 (0.26–1.41) 0.72 (0.22–2.33) 0.80 (0.31–2.04) 1.25 (0.36–4.33)
2002–2008 ref ref ref ref
2009–2014 2.73 (1.14–6.52) 2.16 (0.83–5.58) 1.92 (0.76–4.85) 1.45 (0.54–3.94)
Gravidity
1 0.99 (0.30–3.22) – 0.89 (0.23–3.46) –
2 ref – ref –
ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
aAll characteristics measured at delivery.
virologically suppressed at delivery with this percentage
increasing over time. However, in the first 12 months
postpartum, only 70% were retained in HIV care,
decreasing further during 12 to 24 months postpartum
with less than half of the women remaining in HIV
clinical care.
Others have observed the drop in HIV care continuum
postpartum in the United States. In reports from
Philadelphia and Mississippi, 12-month postpartum
retention was estimated to be just under 40% in both
studies, and 20% in Atlanta among women with perinatal
HIV infection [8,9,11]. Higher rates were observed in
New York State with three-quarters of WLWH with a
live birth remaining in HIV care through 1 year
postpartum [10,24].
A number of factors influence the postpartum retention
estimates available, including how engagement in care was
defined, data sources and differences in study population.
In the Philadelphia and New York State studies, data were
obtained by linking HIVand perinatal surveillance system
records [8,10,24]. In contrast, other studies, including this
one, were based on institutionally available health records
[11,25]. Relying on surveillance system data may allow
for improved capture of HIV care visits, in comparison to
using single-site institutional health records, if women
transfer HIV care postpartum. However, our institution-
based results were comparable to surveillance-based
estimates from New York State [10,24] and higher than
those from Philadelphia [8], as well as, higher than
estimates from the two other studies conducted at single
institutions in Houston [25] and Atlanta [11]. Additional
regional differences in public health policies and
infrastructure available to support pregnant and postpar-
tum women and PLWH care may affect care retention.
Policies including healthcare coverage through Medicaid
and safety net programmes for those without health
insurance may be relevant to observed differences,
including the relatively higher retention rates observed
in New York State and in our cohort [10,12,24].
This study included WLWH living in North Carolina,
which is disproportionately affected by the HIVepidemic,
with high HIV-related morbidity and mortality rates in
comparison to other USA regions [26]. In response, the
North Carolina Division of Public Health has long
supported innovative public health programmes includ-
ing early HIV detection and linkage to HIV care [27–29].
Moreover, at our centre, a coordinated healthcare system
approach to providing care to pregnant WLWH exists,
including coordination between HIV, obstetric and
paediatric providers and colocation of services, including
prenatal, labour and delivery, paediatric and HIV care.
Our coordination of care approach extends from pre-
pregnancy, through pregnancy and into the postpartum
period, with consistency and coordination in HIV and
gynaecologic clinical care providers, and colocation of
services, with reproductive health services provided
during HIV care visits. Postpartum HIV and obstetric
visits were offered through the same clinical care
providers that provided care during pregnancy, with
ART provision based on clinical care guidelines. An
institutional system to contact patients who miss
appointments exists, including follow-up letters, phone
calls and in more recent years, text messages. Notwith-
standing, North Carolina WLWH face ongoing structural
barriers to HIV care engagement [30]. Medicaid covers
pregnancy-related services for low-income women, but
only through 60 days postpartum [31]. Other pro-
grammes designed to provide affordable HIV treatment
exist, however, in a recent study conducted in our source
study population, patients reported ongoing financial
barriers preventing them from accessing HIV care and
ART [32].
In this study, WLWH with longer time on prenatal ART
were more likely to receive recommended postpartum
HIV care. A number of studies have observed that care
received prenatally is associated with postpartum care
outcomes [8–10,24,25]. In part, establishing consistent
care engagement during pregnancy translates to better
postpartum HIV care and clinical outcomes by promoting
patient-level behaviours and addressing existing barriers
to receiving HIV care [12]. In addition, receiving less than
recommended HIV prenatal care may help identify
individuals at a high risk of future inconsistent HIV care
access. Previous work has identified prior care patterns as
a critical factor predicting future HIV care engagement
[33,34]. This suggests that irrespective of the underlying
reasons, identifying individuals early who may be at a high
risk of inconsistently accessing HIV care and tailoring
interventions to this population will be critical to
achieving postpartum and longer-term retention in
care goals.
Consistent with prior studies, older maternal age was
associated with better postpartum HIV care outcomes
[8,9,24,25]. These results are further supported by prior
work in the UCHCC, in Birmingham, Alabama, and a
large North American HIV cohort collaboration showing
that older patients are more likely to receive consistent
HIV care [35–37]. Ensuring adequate retention in care
among younger patients may be especially critical given
that retention in care may be more important to virologic
suppression among younger individuals [38].
HIV RNA suppression rates also dropped precipitously in
the 24 months following childbirth, consistent with our
findings on postpartum HIV care retention, and with
prior literature [8,10,17]. Not surprisingly, virologic
suppression rates increased in more recent calendar years,
consistent with changes in available ART and with
virologic suppression rates observed in the UCHCC
[3,39]. Older mothers were more likely to be virologi-
cally suppressed postpartum possibly reflecting better
ART adherence among older individuals [17]. In
addition, women virologically suppressed at delivery
were more likely to remain virologically suppressed
following childbirth, lending further support to the
central role of prenatal HIV care access on postpartum
HIV care outcomes.
There were several limitations to our study. We were
unable to assess a number of factors likely relevant to
prenatal and postpartum HIV care retention. For
example, qualitative studies have identified stigma, fear,
social support, mental health, intimate partner violence
and logistical factors such as transportation and time
constraints as affecting prenatal and postpartum HIV care
[25,40,41]. In addition, the specific ART regimen
received may further affect HIV care retention, including
the availability of single-tablet regimens. Our study was
nested in an ongoing HIV clinical cohort, which enabled
us to identify pregnant WLWH with available HIV,
prenatal and labour and delivery records. However, it is
possible that women transferred care to another facility
postpartum introducing misclassification and overesti-
mating the proportion of women lost to care. As we relied
on data from a single tertiary care centre, our sample size
was limited and the generalizability of our findings may be
limited geographically. Finally, we restricted our analyses
to 24 months following delivery, and longer follow-up is
needed to estimate effects on HIV clinical outcomes
including morbidity and mortality.
In summary, this study underscores the importance of
adequate prenatal care for retention in HIV care and
improved clinical outcomes in the immediate postpartum
period and beyond. Young women may be at especially
high risk for poor postpartum HIV outcomes, and
interventions tailored to this group are especially needed.
Ensuring access to, and retention in, comprehensive HIV
care is central to individual HIV clinical outcomes, as well
as secondary and perinatal HIV transmission [23,42,43].
A number of strategies to improve retention in HIV care
postpartum have been proposed, including improved care
coordination, perinatal case management, peer support
interventions and use of technology-based interventions
[12]. New recommendations by the American College of
Obstetricians and Gynecologists for a ‘fourth trimester’ of
care for mothers following childbirth may also support
improved postpartum outcomes among WLWH [44].
However, to date, few clinical studies support evidence-
based interventions, and increased attention to improving
women’s prenatal and postpartum HIV healthcare access
is needed.
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